Prague Med. Rep. 2013, 114, 246-257

https://doi.org/10.14712/23362936.2014.14

Presence of Hypogammaglobulinemia – A Risk Factor of Mortality in Patients with Severe Sepsis, Septic Shock, and SIRS

Miroslav Průcha1,*, R. Zazula2, I. Herold3, M. Dostál4,  T. Hyánek5, G. Bellingan6

1Department of Clinical Biochemistry, Hematology and Immunology, Na Homolce Hospital, Prague, Czech Republic
2Department of  Anesthesiology and Intensive Care, First Faculty of Medicine, Charles University in Prague and  Thomayer Hospital, Prague, Czech Republic
3Department of  Anaesthesiology and Intensive Care Medicine, Klaudian’s Hospital, Mladá Boleslav, Czech Republic
4Institute of Experimental Medicine,  Academy of Sciences, Prague, Czech Republic
5Department of Intensive Care Medicine, Na Homolce Hospital, Prague, Czech Republic
6UCL Department of Medicine and NIHR University College London Hospitals, Biomedical Research Centre, London, United Kingdom

References

1. Alejandria, M. M., Lansang, M. A., Dans, L. F., Mantaring Iii, J. B. (2013) Intravenous immunoglobulin for treating sepsis, severe sepsis and septic shock. Cochrane Database Syst. Rev. 9:CD001090, doi: 10.1002/14651858 .CD001090.pub2. <https://doi.org/10.1002/14651858.CD001090.pub2> <PubMed>
2. Anthony, R. M., Kobayashi, T., Wermeling, F., Ravetch, J. V. (2011) Intravenous gammaglobulin suppresses inflammation through a novel T(H)2 pathway. Nature 475, 110–113. <https://doi.org/10.1038/nature10134> <PubMed>
3. Berlot, G., Vassallo, M. C., Busetto, N., Bianchi, M., Zornada, F., Rosato, I., Tartamella, F., Prisco, L., Bigotto, F., Bigolin, T., Ferluga, M., Batticci, I., Michelone, E., Borelli, M., Viviani, M., Tomasini, A. (2012) Relationship between the timing of administration of IgM and IgA enriched immunoglobulins in patients with severe sepsis and septic shock and the outcome: a retrospective analysis. J. Crit. Care 27, 167–171. <https://doi.org/10.1016/j.jcrc.2011.05.012>
4. Bosmann, M., Russkamp, N. F., Patel, V. R., Zetoune, F. S., Sarma, J. V., Ward, P. A. (2011) The outcom of polymicrobial sepsis is independent of T and B cells. Shock 36, 396–340. <https://doi.org/10.1097/SHK.0b013e3182295f5f> <PubMed>
5. Casadevall, A., Pirofski, L. A. (2011) A new synthesis for antibody-mediated immunity. Nat. Immunol. 13, 21–28. <https://doi.org/10.1038/ni.2184> <PubMed>
6. Chong, B. H., Chong, J. J. H. (2010) IVIg immune inhibitory activity: APC is key. Blood 115, 1663–1664. <https://doi.org/10.1182/blood-2009-12-254938>
7. Darenberg, J., Söderquist, B., Normark, B. H., Norrby-Teglund, A. (2004) Differences in potency of intravenous polyspecific immunoglobulin G against streptococcal and staphylococcal superantigens: implications for therapy of toxic shock syndrome. Clin. Infect. Dis. 38, 836–842. <https://doi.org/10.1086/381979>
8. Dellinger, R. P., Levy, M. M., Rhodes, A., Annane, D., Gerlach, H., Opal, S. M., Sevransky, J. E., Sprung, C. L., Douglas, I. S., Jaeschke, R., Osborn, T. M., Nunnally, M. E., Townsend, S. R., Reinhart, K., Kleinpell, R. M., Angus, D. C., Deutschman, C. S., Machado, F. R., Rubenfeld, G. D., Webb, S., Beale, R. J., Vincent, J. L., Moreno, R.; Surviving Sepsis Campaign Guidelines Committee including The Pediatric Subgroup (2013) Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock, 2012. Intensive Care Med. 39, 165–228. <https://doi.org/10.1007/s00134-012-2769-8>
9. Hotchkiss, R. S., Swanson, P. E., Freeman, B. D., Tinsley, K. W., Cobb, J. P., Matuschak, G. M., Buchman, T. G., Karl, I. E. (1999) Apoptotic cell death in patients with sepsis, shock, and multiple organ dysfunction. Crit. Care Med. 27, 1230–1251. <https://doi.org/10.1097/00003246-199907000-00002>
10. INIS Collaborative Group, Brocklehurst, P., Farrell, B., King, A., Juszczak, E., Darlow, B., Haque, K., Salt, A., Stenson, B., Tarnow-Mordi, W. (2011) Treatment of neonatal sepsis with intravenous immune globulin. N. Engl. J. Med. 365, 1201–1211.
11. Kreymann, K. G., de Heer, G., Nierhaus, A., Kluge, S. (2007) Use of polyclonal immunoglobulins as adjunctive therapy for sepsis or septic shock. Crit. Care Med. 35, 2677–2685. <https://doi.org/10.1097/01.CCM.0000295263.12774.97>
12. Laupland, K. B., Kirkpatrick, A. W., Delaney, A. (2007) Polyclonal intravenous immunoglobulin for the treatment of severe sepsis and septic shock in critically ill adults: A systematic review and meta-analysis. Crit. Care Med. 35, 2686–2692. <https://doi.org/10.1097/01.CCM.0000295312.13466.1C>
13. Levy, M. M., Fink, M. P., Marshall, J. C., Abraham, E., Angus, D., Cook, D., Cohen, J., Opal, S. M., Vincent, J. L., Ramsay, G. (2003) 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Intensive Care Med. 29(4), 530–538. <https://doi.org/10.1007/s00134-003-1662-x>
14. Lucas, M., Lee, M., Lortan, J., Lopez-Granados, E., Misbah, S., Chapel, H. (2010) Infection outcomes in patients with common variable immunodeficiency disorders: relationship to immunoglobulin therapy over 22 years. J. Allergy Clin. Immunol. 125, 1354–1360. <https://doi.org/10.1016/j.jaci.2010.02.040>
15. Maddur, M. S., Sharma, M., Hegde, P., Lacroix-Desmazes, S., Kaveri, S. V., Bayry, J. (2013) Inhibitory effect of IVIG on IL-17 production by Th17 cells is independent of anti-IL-17 antibodies in the immunoglobulin preparations. J. Clin. Immunol. 33, S62–S66 (Suppl. 1). <https://doi.org/10.1007/s10875-012-9752-6>
16. Mohr, A., Polz, J., Martin, E. M., Griessl, S., Kammler, A., Pötschke, C., Lechner, A., Bröker, B. M., Mostböck, S., Männel, D. N. (2012) Sepsis leads to a reduced antigen-specific primary antibody response. Eur. J. Immunol. 42, 341–352. <https://doi.org/10.1002/eji.201141692>
17. Moitra, R., Beal, D. R., Belikoff, B. G., Remick, D. G. (2012) Presence of preexisting antibodies mediates survival in sepsis. Shock 37, 56–62. <https://doi.org/10.1097/SHK.0b013e3182356f3e> <PubMed>
18. Myrianthefs, P. M., Boutzouka, A., Baltopoulos, G. J. (2010) γ-globulin levels in patients with community-acquired septic shock. Shock 33, 556–557. <https://doi.org/10.1097/01.shk.0000370606.30525.21>
19. Oksenhendler, E., Gérard, L., Fieschi, C., Malphettes, M., Mouillot, G., Jaussaud, R., Viallard, J. F., Gardembas, M., Galicier, L., Schleinitz, N., Suarez, F., Soulas-Sprauel, P., Hachulla, E., Jaccard, A., Gardeur, A., Théodoro, I., Rabian, C., Debré, P. (2008) DEFI Study Group. Infections in 252 patients with common variable immunodeficiency. Clin. Infect. Dis. 46, 1547–1554. <https://doi.org/10.1086/587669>
20. Raanani, P., Gafter-Gvili, A., Paul, M., Ben-Bassat, I., Leibovici, L., Shpilberg, O. (2009) Immunoglobulin prophylaxis in chronic lymphocytic leukemia and multiple myeloma: systematic review and meta-analysis. Leuk. Lymphoma 50, 764–772. <https://doi.org/10.1080/10428190902856824>
21. Raithatha, A. H., Bryden, D. C. (2012) Use of intravenous immunoglobulin therapy in the treatment of septic shock, in particular severe invasive group A streptococcal disease. Indian J. Crit. Care Med. 16, 37–40. <https://doi.org/10.4103/0972-5229.94433> <PubMed>
22. Rankin, J. S., Oguntolu, O., Binford, R. S., Trochtenberg, D. S., Muhlbaier, L. H., Stratton, C. W. (2011) Management of immune dysfunction after adult cardiac surgery. J. Thorac. Cardiovasc. Surg. 142, 575–580. <https://doi.org/10.1016/j.jtcvs.2011.04.042>
23. Rauch, P. J., Chudnovskiy, A., Robbins, C. S., Weber, G. F., Etzrodt, M., Hilgendorf, I., Tiglao, E., Figueiredo, J. L., Iwamoto, Y., Theurl, I., Gorbatov, R., Waring, M. T., Chicoine, A. T., Mouded, M., Pittet, M. J., Nahrendorf, M., Weissleder, R., Swirski, F. K. (2012) Innate response activator B cells protect against microbial sepsis. Science 335, 597–601. <https://doi.org/10.1126/science.1215173> <PubMed>
24. Smith, K. G., Clatworthy, M. R. (2010) FcgammaRIIB in autoimmunity and infection: evolutionary and therapeutic implications. Nat. Rev. Immunol. 10, 328–343. <https://doi.org/10.1038/nri2762> <PubMed>
25. Taccone, F. S., Stordeur, P., De Backer, D., Creteur, J., Vincent, J. L. (2009) Gamma globulin levels in patients with community acquired septic shock. Shock 32, 379–385. <https://doi.org/10.1097/SHK.0b013e3181a2c0b2>
26. Turgeon, A. F., Hutton, B., Fergusson, D. A., McIntyre, L., Tinmouth, A. A., Cameron, D. W., Hébert, P. C. (2007) Meta-analysis: intravenous immunoglobulin in critically ill adult patients with sepsis. Ann. Intern. Med. 146, 193–201. <https://doi.org/10.7326/0003-4819-146-3-200702060-00009>
27. Vassilev, T., Bauer, M. (2012) Passive immunotherapy of sepsis with intravenous immune globulin: not all IVIg preparations are created equal. Crit. Care 16, 407. <https://doi.org/10.1186/cc10607> <PubMed>
28. Werdan, K., Pilz, G., Bujdoso, O., Fraunberger, P., Neeser, G., Schmieder, R. E., Viell, B., Marget, W., Seewald, M., Walger, P., Stuttmann, R., Speichermann, N., Peckelsen, C., Kurowski, V., Osterhues, H. H., Verner, L., Neumann, R., Müller-Werdan, U. (2007) Score-Based Immunoglobulin Therapy of Sepsis (SBITS) Study Group: Score-based immunoglobulin G therapy of patients with sepsis: the SBITS study. Crit. Care Med. 35, 2693–2701. <https://doi.org/10.1097/01.CCM.0000295426.37471.79>
29. Yavuz, L., Aynali, G., Aynali, A., Alaca, A., Kutuk, S., Ceylan, B. G. (2012) The effects of adjuvant immunoglobulin M-enriched immunoglobulin therapy on mortality rate and renal function in sepsis-induced multiple organ dysfunction syndrome: retrospective analysis of intensive care unit patients. J. Int. Med. Res. 40, 1166–1174. <https://doi.org/10.1177/147323001204000337>
front cover

ISSN 1214-6994 (Print) ISSN 2336-2936 (Online)

Archive